PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för miltefosine. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

23 hits

Bibliografisk träff 2013-08-23

Miltefosine-unresponsive Leishmania donovani has a greater ability than miltefosine-responsive L. donovani to resist reactive oxygen species.

Das M, Saudagar P, Sundar S, Dubey VK.

FEBS J · research support, non-u.s. gov't; journal article · DOI 10.1111/febs.12449

Bibliografisk träff 2013-08-01

Miltefosine suppresses inflammation in a mouse model of inflammatory bowel disease.

Verhaar AP, Wildenberg ME, te Velde AA, Meijer SL, Vos AC, Duijvestein M, Peppelenbosch MP, Hommes DW, van den Brink GR.

Inflamm Bowel Dis · journal article · DOI 10.1097/mib.0b013e3182917a2b

Bibliografisk träff 2013-07-18

Treatment of mucosal leishmaniasis (L. infantum) with miltefosine in a patient with Good syndrome.

Stoeckle M, Holbro A, Arnold A, Neumayr A, Weisser M, Blum J.

Acta Trop · journal article; case reports · DOI 10.1016/j.actatropica.2013.07.002

Bibliografisk träff 2013-07-16

In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens.

Biswas C, Sorrell TC, Djordjevic JT, Zuo X, Jolliffe KA, Chen SC.

J Antimicrob Chemother · research support, non-u.s. gov't; journal article · DOI 10.1093/jac/dkt282

Bibliografisk träff 2013-06-28

Effect of miltefosine on erythrocytes.

Munoz C, Alzoubi K, Jacobi J, Abed M, Lang F.

Toxicol In Vitro · research support, non-u.s. gov't; journal article · DOI 10.1016/j.tiv.2013.06.010

Bibliografisk träff 2013-06-24

Edelfosine and miltefosine effects on lipid raft properties: membrane biophysics in cell death by antitumor lipids.

Castro BM, Fedorov A, Hornillos V, Delgado J, Acuña AU, Mollinedo F, Prieto M.

J Phys Chem B · research support, non-u.s. gov't; journal article · DOI 10.1021/jp401407d

Bibliografisk träff 2013-06-01

Apoptosis-like cell death pathways in the unicellular parasite Toxoplasma gondii following treatment with apoptosis inducers and chemotherapeutic agents: a proof-of-concept study.

Ni Nyoman AD, Lüder CG.

Apoptosis · research support, non-u.s. gov't; research-article; journal article · DOI 10.1007/s10495-013-0832-8

Bibliografisk träff 2013-06-01

Post-kala-azar dermal leishmaniasis with mucosal involvement: an unusual case presentation including successful treatment with miltefosine.

Salam MA, Siddiqui MA, Nabi SG, Bhaskar KR, Mondal D.

J Health Popul Nutr · research-article; journal article; case reports · DOI 10.3329/jhpn.v31i2.16395

Bibliografisk träff 2013-05-31

Effectiveness of miltefosine treatment in targeting anti-leishmanial HO-1/Nrf-2-mediated oxidative responses in visceral leishmaniasis patients.

Das S, Pandey K, Rabidas VN, Mandal A, Das P.

J Antimicrob Chemother · research support, non-u.s. gov't; journal article · DOI 10.1093/jac/dkt162

Bibliografisk träff 2013-05-21

Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitis.

Polat ZA, Walochnik J, Obwaller A, Vural A, Dursun A, Arici MK.

Clin Exp Ophthalmol · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1111/ceo.12120

Bibliografisk träff 2013-05-15

Interactions of alkylphosphocholines with model membranes-the Langmuir monolayer study.

Wnętrzak A, Lątka K, Dynarowicz-Łątka P.

J Membr Biol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1007/s00232-013-9557-4

Bibliografisk träff 2013-05-01

Post-kala-azar dermal leishmaniasis developing in miltefosine-treated visceral leishmaniasis.

Koley S, Mandal RK, Choudhary S, Bandyopadhyay A.

Indian J Dermatol · journal article; case-report · DOI 10.4103/0019-5154.110848

Bibliografisk träff 2013-02-19

Susceptibility of clinical isolates of Leishmania aethiopica to miltefosine, paromomycin, amphotericin B and sodium stibogluconate using amastigote-macrophage in vitro model.

Utaile M, Kassahun A, Abebe T, Hailu A.

Exp Parasitol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.exppara.2013.01.022

Bibliografisk träff 2013-01-29

Interactions of antileishmanial drugs with monolayers of lipids used in the development of amphotericin B-miltefosine-loaded nanocochleates.

Pham TT, Barratt G, Michel JP, Loiseau PM, Saint-Pierre-Chazalet M.

Colloids Surf B Biointerfaces · research support, non-u.s. gov't; journal article · DOI 10.1016/j.colsurfb.2013.01.041

Bibliografisk träff 2013-01-01

Thermotherapy effective and safer than miltefosine in the treatment of cutaneous leishmaniasis in Colombia.

López L, Cruz C, Godoy G, Robledo SM, Vélez ID.

Rev Inst Med Trop Sao Paulo · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1590/s0036-46652013000300011

Bibliografisk träff 2012-12-13

Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani.

Kulshrestha A, Bhandari V, Mukhopadhyay R, Ramesh V, Sundar S, Maes L, Dujardin JC, Roy S, Salotra P.

Parasitol Res · comparative study; research support, non-u.s. gov't; validation study; journal article · DOI 10.1007/s00436-012-3212-3

Bibliografisk träff 2012-12-12

Case report: Transient success using prolonged treatment with miltefosine for a patient with diffuse cutaneous leishmaniasis infected with Leishmania mexicana mexicana.

Ordaz-Farias A, Muñoz-Garza FZ, Sevilla-Gonzalez FK, Arana-Guajardo A, Ocampo-Candiani J, Treviño-Garza N, Becker I, Camacho-Ortiz A.

Am J Trop Med Hyg · journal article; case reports; case-report · DOI 10.4269/ajtmh.2012.11-0592

Bibliografisk träff 2012-11-30

Adherence to miltefosine treatment for visceral leishmaniasis under routine conditions in Nepal.

Uranw S, Ostyn B, Dorlo TP, Hasker E, Dujardin B, Dujardin JC, Rijal S, Boelaert M.

Trop Med Int Health · research support, non-u.s. gov't; journal article · DOI 10.1111/tmi.12025

Bibliografisk träff 2012-11-19

Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis.

Wiederhold NP, Najvar LK, Bocanegra R, Kirkpatrick WR, Sorrell TC, Patterson TF.

Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1128/aac.01624-12

Bibliografisk träff 2012-11-08

Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial.

Sundar S, Sinha P, Jha TK, Chakravarty J, Rai M, Kumar N, Pandey K, Narain MK, Verma N, Das VN, Das P, Berman J, Arana B.

Trop Med Int Health · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1111/tmi.12015

Bibliografisk träff 2012-09-19

Effect of alkylphospholipids on Candida albicans biofilm formation and maturation.

Vila TV, Ishida K, de Souza W, Prousis K, Calogeropoulou T, Rozental S.

J Antimicrob Chemother · research support, non-u.s. gov't; journal article · DOI 10.1093/jac/dks353

Bibliografisk träff 2012-08-27

Proapoptotic miltefosine nanovesicles show synergism with paclitaxel: Implications for glioblastoma multiforme therapy.

Thakur A, Joshi N, Shanmugam T, Banerjee R.

Cancer Lett · journal article · DOI 10.1016/j.canlet.2012.08.022

Bibliografisk träff 2012-08-05

Miltefosine: a novel treatment option for mast cell-mediated diseases.

Maurer M, Magerl M, Metz M, Weller K, Siebenhaar F.

J Dermatolog Treat · review; journal article · DOI 10.3109/09546634.2012.671909